Latest News

VIRALEZE COVID-19 nasal spray study to commence in January

Dec 22nd, 2020

Starpharma today announced that it has received all necessary approvals to commence its clinical study for VIRALEZE™. The study will commence enrolment of healthy volunteers in Perth in early January 2021 and is expected to be completed in Q1 2021. This study is being undertaken to support commercialisation activities for VIRALEZE™, and is not a requirement to achieve EU product registration.  

Read More

VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21

Dec 10th, 2020

Starpharma today announced significant commercial and regulatory progress has been made for VIRALEZE™ nasal spray with the EU regulatory dossier more than 90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021. This timing is earlier than previously announced.

Read More

AGM Chairman address and CEO presentation

Nov 20th, 2020

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.


Read More

SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray

Nov 19th, 2020

Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.


Read More

In the media

Starpharma Viraleze: COVID-19 Nasal Spray Development

Nov 20th, 2020

Seeking Alpha, a financial market portal featured a piece on Starpharma’s latest update on its VIRALEZE™ COVID-19 nasal spray. The article noted the potential of the spray and Starpharma’s latest regulatory developments on this front. To read the full article click here.

Read More

Starpharma (ASX:SPL) banks $5.7M government R&D tax refund

Oct 21st, 2020

The Market Herald reported that Starpharma are to receive a $5.7 million research and development (R&D) tax incentive refund from the Federal Government following the government’s program to  support companies taking on R&D that benefits Australia. To watch the full video click here.

Read More

Biotech In Focus In 2020

Oct 16th, 2020

Online financial news platform FN Arena recently published an article which highlighted six biotech ASX-listed companies that have recently been viewed positively by analysts. Starpharma was listed as one such company, stating that Bell Potter had emphasized the company’s strong growth potential. To read the full article click here

Read More

$2B R&D win for biotech, resources

Oct 8th, 2020

Starpharma was featured in an article by Stockhead, an online publication that delivers news on ASX-listed small and mid-cap companies. The piece looked at the Federal Government’s decision to abandon plans to reduce R&D tax refund by $1.8B, and will instead add $200M in value to the incentive. The article noted Starpharma received a $4.9M tax refund in December 2019 for R&D associated with the development of its DEP drug delivery system and VivaGel BV women’s health products.

To read the full article click here.


Read More

Shareholder Updates

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP® docetaxel update & patient case study

>> DEP® cabazitaxel update & patient case study

>> Multiple DEP® products showcased at AACR 2020 Annual Meeting

>> New DEP® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP® remdesivir

>> DEP® partnering, including Antibody Drug Conjugates

>> DEP® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

Read More

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan 

>> DEP® patient case studies

>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received

>> New DEP® ADC programs

>> DEP® pipeline targets multiple high-value areas

>> Other DEP® programs

>> Outlook, recent news & events


Read More

Sign up to receive news here